Organization
Sun Yat-sen University Cancer Center, Guangzhou, China
14 abstracts
Abstract
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Yunnan Cancer Hospital, Kunming, China, Sun Yat-sen University Cancer Center, Guang Zhou, China,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, Jiangsu Province Hospital, Nanjing, China, Hunan Cancer Hospital, Changsha, China, Shandong Cancer Hospital and Institute, Jinan, China, Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).Org: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, The First People's Hospital of Foshan,
Abstract
Phase I study of TQB3728 tablets, an oral inhibitor of apoptosis proteins in patients with advanced solid tumor.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Pretreatment neutrophil to lymphocyte ratio as a predictor of pathological complete response to neoadjuvant immunotherapy in early breast cancer.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,
Abstract
Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study.Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Zhongshan Hospital, Fudan University, Shanghai, China, Departments of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China, Haerbin, China,
Abstract
Palbociclib, trastuzumab, pyrotinib and fulvestrant in patients with brain metastasis from ER/PR positive, HER-2 positive breast cancer: Report from an interim analysis of a multicenter, prospective study in China.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Affiliated cancer hospital of Guangxi Medical University, Guangxi, China,
Abstract
TIPS combined with lenvatinib and PD-1 inhibitor in patients with advanced HCC with symptomatic portal hypertension: A retrospective study.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study.Org: The Fifth Affiliated Hospital of Sun Yet-Sen University, Zhuhai, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Zhuhai Hospital of lntegrated Traditional Chinese and Western Medicine, Zhuhai, China, Department of Breast Surgery, Zhuhai Maternity and Child Health Hospital, Zhuhai, China, The First People's Hospital of Zhaoqing, Zhaoqing, China,
Abstract
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Hunan Cancer Hospital, Changsha, China, Yunnan Cancer Hospital, Kunming, China, The First Affiliated Hospital of Anhui Medical University, Hefei, China,
Abstract
Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.Org: Qilu Hospital of Shandong University, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Nimotuzumab in combination with intensity modulated radiotherapy improve survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multicenter-based real-world study.Org: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Sichuan Cancer hospital institute, Chengdu, China, Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, PLA General Hospital, Beijing, China, Sun Yat-sen University Cancer Center, Guangzhou, China,